At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 528 enrolled
Drug / intervention
NoV Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
In Brief
A Phase 2 clinical trial evaluating NoV Vaccine for Healthy Volunteers and Norovirus. Completed, enrolled 528 participants across 11 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate descriptively the long-term immunogenicity of at least 1 NoV vaccine administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Norovirus
CountriesBelgium, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartFeb 2017
Primary CompletionJul 2021
TodayJul 2026
First PostedFeb 1, 2017
Enrollment StartFeb 21, 2017
Primary CompletionJul 22, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.4 years ago
Interventions
NoV Vaccinebiological
NoV vaccine injection administered.